A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study)-Reference-Cited by-同舟云学术

A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study)

Published:2017-06-15 Issue:2 Volume:29 Page:273-283
ISSN:0937-3462
Container-title:International Urogynecology Journal
language:en
Short-container-title:Int Urogynecol J

Author:

Staskin David,Herschorn Sender,Fialkov Jonathan,Tu Le Mai,Walsh Terry,Schermer Carol R.

Funder

Astellas Pharma Inc

Publisher

Springer Science and Business Media LLC

Subject

Urology,Obstetrics and Gynecology

Link

http://link.springer.com/article/10.1007/s00192-017-3377-5/fulltext.html

Reference22 articles.

1. Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, et al. An International Urogynecological association (IUGA)/International continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J. 2010;21(1):5–26.

2. Drake MJ. Do we need a new definition of the overactive bladder syndrome? ICI-RS 2013. Neurourol Urodyn. 2014;33(5):622–4.

3. Coyne KS, Sexton CC, Irwin DE, Kopp ZS, Kelleher CJ, Milsom I. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int. 2008;101(11):1388–95.

4. Maman K, Aballea S, Nazir J, Desroziers K, Neine ME, Siddiqui E, et al. Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison. Eur Urol. 2014;65(4):755–65.

5. Khullar V, Amarenco G, Angulo JC, Cambronero J, Hoye K, Milsom I, et al. Efficacy and tolerability of mirabegron, a beta(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol. 2013;63(2):283–95.

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mirabegron 50 mg once daily, long-term treatment maximizes benefit in middle-aged and older people with overactive bladder syndrome: a systematic review and meta-analysis of nine phase II/III, randomized, double-blind, parallel-design, placebo-controlled, multicenter, and multinational trials;Frontiers in Surgery;2024-08-26

2. Drug–Drug Interactions between Tamsulosin and Mirabegron in Healthy Individuals Do Not Affect Pharmacokinetics and Hemodynamic Parameters Significantly;Pharmaceuticals;2023-10-13

3. Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis;Revista Brasileira de Ginecologia e Obstetrícia / RBGO Gynecology and Obstetrics;2023-06

4. Adherence to Overactive Bladder Syndrome Treatments Recent Developments and Future Perspectives;International Journal of Women's Health;2023-05

5. TReating Incontinence for Underlying Mental and Physical Health (TRIUMPH): a study protocol for a multicenter, double-blinded, randomized, 3-arm trial to evaluate the multisystem effects of pharmacologic treatment strategies for urgency-predominant urinary incontinence in ambulatory older women;Trials;2023-04-21